Back to ARROWSTREET CAPITAL, LIMITED PARTNERSHIP ARROWSTREET CAPITAL, LIMITED PARTNERSHIP

ACADACAD
Showing 5 of 15 quarters

Position history for ARROWSTREET CAPITAL, LIMITED PARTNERSHIPARROWSTREET CAPITAL, LIMITED PARTNERSHIP's holdings in ACADIA PHARMACEUTICALS INC

Yes. Arrowstreet Capital holds 1,969,445 shares of ACAD (Acadia Pharmaceuticals), worth $49.8M, as of its Q2 2026 13F filing. It increased the position by 399,954 shares (+25.5%) from Q1 2026. Arrowstreet Capital has held ACAD since Q2 2025, across 5 quarterly 13F filings.

Current Value

$49.8M

Current Shares

2M

Total Value Change

+$42.6M

Total Shares Change

+1.6M

Quarter-by-Quarter History
QuarterActionSharesChangeValueWeightPriceConviction
2026-Q2
Latest
Increased
2M
+25.5%
$49.8M0.0%$25.30
36
2026-Q1
Increased
1.6M
+4.5%
$34.9M0.0%$22.26
30
2025-Q4
Decreased
1.5M
-8.9%
$40.1M0.0%$26.71
0
2025-Q3
Increased
1.6M
+390.1%
$35.2M0.0%$21.34
47
2025-Q2
New
336,438
-
$7.3M0.0%$21.57
38

Other major holders of ACAD: BAKER BROS. ADVISORS LP

Analytics tracking helps us improve the product. Essential functions stay on either way. How analytics data is used